Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1995;77:575-583

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snyders, D. J.
Right arrow Articles by Yeola, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyders, D. J.
Right arrow Articles by Yeola, S. W.
(Circulation Research. 1995;77:575-583.)
© 1995 American Heart Association, Inc.


Articles

Determinants of Antiarrhythmic Drug Action

Electrostatic and Hydrophobic Components of Block of the Human Cardiac hKv1.5 Channel

Dirk J. Snyders, Sarita W. Yeola

From the Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract The molecular basis of antiarrhythmic drug action is still poorly understood. We recently reported that block of the human cardiac hKv1.5 channel by quinidine displayed similarity with internal quaternary ammonium block of squid and Shaker potassium channels. To gain further insight into the molecular determinants of the affinity and the stereoselectivity of antiarrhythmic drug action, we studied the effects of quinine (a diastereomer of quinidine), clofilium (a quaternary ammonium class III agent), and tetrapentylammonium (TPeA, a biophysical reference probe for the internal quaternary ammonium binding site). For all compounds, block was voltage dependent, with a steep increase over the voltage range of channel opening and a superimposed weaker voltage dependence at more positive potentials. The latter electrostatic component was similar for all drugs, consistent with a binding reaction sensing {approx}20% of the transmembrane electrical field. Clofilium and TPeA displayed a higher apparent affinity (0.15 and 0.28 µmol/L, respectively), and quinine displayed a lower one (21 µmol/L) compared with quinidine (6.2 µmol/L). Block development upon depolarization was time dependent for clofilium and TPeA but slow compared with quinidine. A time-dependent component was difficult to resolve for quinine, but the time course of deactivating tail currents was slower than in the control condition. The resulting crossover phenomenon was also observed for the quaternary drugs. Compared with TPeA alone, the combined application of quinine and TPeA resulted in a reduced current that decayed slower, consistent with competition. When a bimolecular model for open-channel block was used, the apparent association rate constants for these drugs were found to be similar [range, 4.5 to 7.7 (µmol/L)-1 · s-1]. The apparent dissociation rate constants for clofilium (1.9 s-1) and TPeA (3.6 s-1) were smaller compared with quinidine (34 s-1), whereas that for quinine was faster (>=125 s-1). This large range in dissociation rate constants could explain the differences between these drugs both in kinetics and affinity. The results are consistent with a general model in which these agents act as cationic open-channel blockers but with an affinity largely determined by the intrinsic stability of the drug-receptor complex. Hydrophobic interactions are most likely involved in this stabilization of binding.


Key Words: K+ channels • antiarrhythmia agents • quaternary ammonium • quinidine • clofilium


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Potassium channels regulate excitability of cardiac cells at various levels. They contribute to maintenance of the resting potential, early repolarization, control of action potential duration, and pacemaking activity.1 Prolongation of action potential duration and cardiac refractoriness represents one modality of antiarrhythmic action (class III action).2 Therefore, potassium channels that open in the voltage range of the plateau are potential molecular targets of class III antiarrhythmic agents. Drug-channel interactions have been studied in myocytes isolated from various animal species and, more recently, from human hearts. A major problem in the investigation of basic mechanisms of drug-channel interaction is posed by the need to eliminate multiple overlapping ionic conductances. Heterologous expression of cloned channels can be used to circumvent this problem: the human cardiac potassium channel hKv1.5 can be stably expressed in L cells, from which the current can be recorded without contamination from other voltage-gated currents.3 The properties of hKv1.5 include activation positive to -30 mV, fast activation kinetics, slow and incomplete inactivation, outward rectification, and high sensitivity to 4-aminopyridine.3 Recently, functionally similar currents have been identified in rat and canine myocytes4 5 6 and in human atrial myocytes.7 The properties of the human atrial current are highly similar to those obtained for hKv1.5 in the heterologous expression system.3 7 Therefore, the expression system provides an important tool for the study of functional and pharmacological characteristics of (human) cardiac ion channels.

We have exploited its advantages to demonstrate that quinidine, one of the most widely used antiarrhythmic agents in the United States, blocks the hKv1.5 channel at clinically relevant concentrations.8 The results indicated that quinidine acts in its cationic form as an open-channel blocker, binding in the internal mouth of the channel and sensing {approx}20% of the electrical field. This mechanism of block displayed similarity to the block of other delayed rectifier potassium channels by quaternary ammonium derivatives.9 10 To gain more insight into the determinants of drug binding in the bimolecular drug-channel interaction, we now report on the effects of tetrapentylammonium (TPeA), clofilium (a quaternary ammonium class III agent),11 and quinine (a diastereomer of quinidine). We tested for state, time, and voltage dependence of drug action. The data suggest a general model in which these agents act as cationic open-channel blockers but with the affinity and kinetics largely determined by the intrinsic stability of the drug-channel receptor complex.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Transfection and Cell Culture
We used the stable cell line expressing hKv1.5 that has been described in detail elsewhere.3 Cells were cultured in DMEM supplemented with 10% horse serum and 0.25 mg/mL G418. The cultures were passed every 4 to 5 days by using a brief trypsin treatment. Before experimental use, subconfluent cultures were incubated with 2 µmol/L dexamethasone for 24 hours to induce efficient channel expression. The cells were removed from the dish with a rubber policeman, stored at room temperature, and used within 12 hours.

Electrical Recording
Recordings were made with an Axopatch-1A or an Axopatch-200A patch-clamp amplifier (Axon Instruments) by using the whole-cell configuration of the patch-clamp technique.12 Micropipettes were pulled from Starbore borosilicate glass (Radnoti Glass Co) and were heat-polished. Currents were recorded at room temperature (21°C to 23°C) and were sampled at 2 to 10 kHz after anti-alias filtering at 1 to 5 kHz. Data acquisition and command potentials were controlled by a versatile custom-made programmable stimulator. To ensure voltage-clamp quality, electrode resistance was kept at <3 M{Omega}; the average resistance was 2.1±0.2 M{Omega} (n=28). Junction potentials were zeroed with the electrode in the standard bath solution. Gigaohm seal formation was achieved by suction (19±3 G{Omega}; range, 6 to 50 G{Omega}). After establishing the whole-cell configuration, the capacitive transients elicited by symmetrical 10-mV voltage-clamp steps from -80 mV were recorded at 50 kHz (filtered at 10 kHz) for calculation of capacitive surface area, access resistance, and input impedance. The average access resistance was 3.7±0.2 M{Omega}, and after compensation, the residual access resistance was 1.1±0.2 M{Omega}. With an average current of 2.1±0.2 nA at +60 mV (ie, largest currents associated with strongest depolarization), voltage errors, based on the calculated residual access resistance, were <2.5 mV.

Solutions and Chemicals
The "intracellular" pipette filling solution contained (mmol/L) KCl 110, HEPES 10, K4BAPTA 5, K2ATP 5, and MgCl2 1 and was adjusted to pH 7.2 with KOH, yielding a final intracellular potassium concentration of {approx}145 mmol/L. The bath solution contained (mmol/L) NaCl 130, KCl 4, CaCl2 1.8, MgCl2 1, HEPES 10, and glucose 10 and was adjusted to pH 7.35 with NaOH. Quinidine (quinidine gluconate) was obtained from Eli-Lilly. Clofilium was a gift from Eli-Lilly. The lipid solubility (logP) of clofilium (based on octanol:phosphate buffer pH 7.4 partitioning) is 0.75. All other chemical compounds were obtained from Sigma Chemical Co. All drugs were added from aqueous stock solutions.

Pulse Protocols and Analysis
The holding potential was -80 mV unless indicated otherwise. After obtaining control data, bath perfusion was switched to drug-containing solution. Effects of drug infusion or removal were monitored with test pulses from -80 to +50 mV, applied every 20 seconds until steady state was obtained. The cycle time for other protocols was 10 seconds or slower with quinidine and quinine. In the presence of clofilium and TPeA, the cycle time was slowed to 20 seconds because of their slow kinetics.

The standard protocol to obtain current-voltage relations and activation curves consisted of 250-millisecond pulses that were imposed in 10-mV increments between -80 and +60 mV, with additional interpolated pulses to yield 5-mV increments between -30 and +10 mV (activation range of hKv1.5). The "steady state" current-voltage relations were obtained by measuring the current at the end of the 250-millisecond depolarizations. Longer pulses (500 to 750 milliseconds) were used with the lower concentrations of TPeA and clofilium, which induced block slowly (see "Results"). For voltages between -80 and -40 mV, we only observed passive linear leak; least-squares fits to these data were used for leak correction. Capacitive transients were subtracted by using an appropriately scaled average of 16 to 32 hyperpolarizing pulses from -80 to -100 mV. Deactivating tail currents were recorded at -30 or -50 mV. The activation curve was obtained from the tail-current amplitude immediately after the capacitive transient. For steady state curves, raw data points were averaged over a small time window (2 to 5 milliseconds). Raw tracings shown for the present study were corrected for linear leak and capacitive transients as described above and digitally filtered at 1 to 2 kHz in the frequency domain after Fourier transformation.

The time courses of tail currents, slow inactivation, and drug-induced kinetic changes were fitted with a sum of exponentials. The curve-fitting procedure used a nonlinear least-squares (Gauss-Newton) algorithm; results were displayed in a linear and semilogarithmic format together with a plot of the residual deviations of the data from the fitted curve (difference plot). Goodness of the fit and required number of exponential components were judged by comparing {chi}2 values statistically (F test) and by inspection for systematic nonrandom trends in the difference plot.

Analysis of Drug Action
The amount of block was determined as follows: leak-corrected current in the presence of drug (Idrug) was normalized to matching control current (Icontrol) to yield fractional block (f=1-Idrug/Icontrol). Using a first-order blocking scheme to describe the drug-channel interaction, we obtained apparent affinity Kd and Hill coefficient n from fitting the fractional block f at various drug concentrations ([D]) with (1) f=1/{1+(Kd/[D])n}

The apparent rate constants for binding (k) and unbinding (l) were obtained from fits to (2) {lambda}=kx[D]+l

in which {lambda} is the inverse of the time constant {tau} B of block development. A problem with this linearization is potential inappropriate weighting of the data. Therefore, we fitted both the linear equation (Equation 2) and the hyperbolic function {tau}B=1/(kx[D]+l) to the data. Data are shown in the linear format.

To analyze the voltage dependence of block, we determined fractional block f at each voltage above -30 mV. Using data points in the range of full channel opening (see "Results"), the voltage dependence of block was fitted with the Woodhull formalism13 : (3) f=[D]/{[D]+Kd*xexp(-{delta}zFE/RT)}

where F is the Faraday constant, R is the gas constant, E is the imposed voltage, T is the absolute temperature, and z is the valence (+1 for quaternary ammoniums and cationic quinidine or quinine). The parameter {delta} represents the fractional electrical distance, ie, the fraction of the transmembrane electrical field sensed by a single charge at the receptor site. Kd* represents the affinity at the reference voltage (0 mV). This represents a direct approach to analysis of the voltage dependence of block rather than the indirect approach, in which the same data (normalized block) are converted into an apparent affinity, which is subsequently fitted with the exponential Kd(E)=Kd*xexp(-{delta}zFE/RT).

Mathematical Modeling and Statistics
The activation time course of hKv1.5 is sigmoidal3 and presumably requires activation of four subunits. Activation of Shaker-related channels is a complicated process, details of which require mathematical models with up to 16 kinetic states.14 15 In addition, the hKv1.5 channel displays slow inactivation with two or three exponential components.3 For the purpose of modeling drug-channel interactions, we simplified the kinetic model (see diagram in Fig 8Down) as follows: (1) channel opening was described by independent activation of four subunits, and (2) slow inactivation was omitted. To reproduce the time course of channel opening and tail current deactivation, rate constants for subunit activation ({alpha}) and deactivation (ß) were set to 400 and 1 s-1 (at +50 mV), respectively, and 0.1 and 7 s-1 at -40 mV, respectively. This model is similar to that used previously to describe the interaction of quinidine with hKv1.5.8 For these simulations, we used the fourth-order Runge-Kutta ordinary differential equation solver of the MATLAB software (The MathWorks Inc).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 8. Mathematical model of open-channel block. Channel opening was modeled by using four independent activating units (see diagram) reflecting the fourfold symmetry of the channel. Values for {alpha} and ß are given in "Materials and Methods." A, Simulation of the time course of block for clofilium. Increasing the concentration accelerated the time-dependent block but also resulted in a reduction of peak current that was solely due to open-channel block. B, Modification of the dissociation rate with fixed association rate. The binding rate constant (k) was fixed at 6 (µmol/L)-1 · s-1, and the dissociation rate constant (l) was varied between 2 and 120 s-1. The tracings represent, in each case, the time course for the drug concentration ([D]) corresponding to the affinity, which was 0.3, 5, and 20 µmol/L, respectively. With a low l value, both high affinity and slow time course were reproduced. As the l value was increased, the size of the time-dependent component became progressively smaller. C indicates closed states; O, the open-channel state; and OB, the blocked open-channel state.

Results are expressed as mean±SEM. ANOVA with appropriate post hoc comparisons was used to compare the differences in mean values; a value of P<.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Clofilium, TPeA, and Quinine Inhibit hKv1.5 Currents
Fig 1Down illustrates the effects of TPeA, clofilium, and quinine on hKv1.5 currents expressed in L cells. All compounds were effective when added to the bath superfusion solution, but >=20 minutes was required to achieve steady state effects with TPeA and clofilium. This was an order of magnitude slower than the time needed for complete exchange of extracellular solution (<2 minutes). The effects of quinidine and quinine reached steady state more quickly (<10 minutes) and were reversible upon washout. With TPeA and clofilium, only partial reversal was observed upon washout ({approx}30% recovery in 30 minutes).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 1. Inhibition of hKv1.5 current by tetrapentylammonium (TPeA), clofilium, and quinine. Current tracings are shown for depolarizations between -30 and +50 mV in 10-mV increments, holding potential of -80 mV, and tail currents at -30 mV. A, Control. B, TPeA at 1 µmol/L. C, TPeA at 20 µmol/L. D and E, Control and 0.3 µmol/L clofilium. F, Clofilium at 3 µmol/L. Results for clofilium are from two different cells with similar current size in the control condition. G, Control. H, Quinine at 6 µmol/L. I, Quinine at 20 µmol/L. Vertical calibration is 1 nA. Note the compressed time scale for the clofilium tracings. Both quaternary drugs induced a qualitatively similar time-dependent relaxation of hKv1.5 current after initial channel opening. Quinine was less potent and did not induce the time-dependent decline as seen for concentrations resulting in equivalent levels of inhibition for TPeA or clofilium (compare panel I with panels B and E).

TPeA was used as a reference probe for the putative internal quaternary ammonium site9 10 because it should be more membrane permeant than tetraethylammonium (TEA) on the basis of its 100-fold higher lipid solubility.16 After application of TPeA (Fig 1AUp through 1C), the current upon depolarization initially rose as in the control condition. Upon reaching a slightly reduced peak current level, the hKv1.5 current declined in a time-dependent manner to a lower steady state level. This relaxation process superficially resembled channel inactivation but can most easily be explained by a shift toward a higher binding affinity, resulting in a time-dependent relaxation to the new equilibrium between blocked and drug-free channels. Consistent with the high level of block induced during the depolarizing pulse, the tail currents were largely suppressed compared with the control condition. For the quaternary ammonium class III antiarrhythmic agent clofilium, a similar pattern was observed, as shown in Fig 1DUp through 1F. A marked time-dependent relaxation to a high level of block was observed after equilibration with 300 nmol/L clofilium (Fig 1EUp), with more extensive block at 3 µmol/L clofilium (Fig 1FUp).

To determine possible stereoselectivity in hKv1.5 block, we tested whether quinine, a diastereomer of quinidine, interacted with this channel (Fig 1HUp through 1I). Quinine clearly suppressed the hKv1.5 current in a concentration-dependent manner. However, in contrast to TPeA and clofilium, a time-dependent relaxation was not readily resolved, despite a reduction of hKv1.5 current by {approx}50% with 20 µmol/L quinine.

Concentration Dependence of hKv1.5 Inhibition
Fig 2Down shows the concentration dependence of hKv1.5 inhibition. For most concentrations, the suppression of hKv1.5 current after 250 milliseconds was used as an index of block. However, at the lowest concentrations of TPeA and clofilium, the interaction with hKv1.5 was too slow to reach steady state within this time window. In that case, the suppression after 500 or 750 milliseconds was compared with the control condition. The dashed line in Fig 2Down illustrates the concentration dependence of hKv1.5 block by quinidine, with an apparent Kd of 6.2 µmol/L as described previously.8 Both TPeA and clofilium were more potent than quinidine, with apparent affinities of 280 and 150 nmol/L, respectively. In contrast, the apparent affinity for quinine was significantly less (21 µmol/L). The concentration dependence for hKv1.5 inhibition was well approximated with a Hill coefficient of 1, consistent with a bimolecular reaction as was previously reported for quinidine.8 Admittedly, this could not be rigorously assessed for clofilium because of the inability to separate slow and limited block at low concentrations (<300 nmol/L) from the normal slow and partial inactivation of hKv1.5. To limit the latter, we attempted to quantify the level of block by using pulse trains with 250-millisecond depolarizations. However, even at 1 µmol/L this usually resulted in somewhat lower levels of block, which were presumably due to unblocking between depolarizations.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 2. Concentration dependence of hKv1.5 inhibition by clofilium, tetrapentylammonium (TPeA), quinidine, and quinine. Relative suppression of hKv1.5 current (f=1-Idrug/Icontrol, where f is fractional block and Idrug and Icontrol are current in the presence of drug and control current, respectively) at +50 mV for three to six determinations at each concentration is shown as mean±SEM. The solid lines are a fit to the data with the Hill equation (see "Materials and Methods") with a Hill coefficient of 1. The Kd values were 0.15, 0.28, and 20.6 µmol/L for clofilium, TPeA, and quinine, respectively (see TableUp for statistics). The dashed line represents the dose-response curve for quinidine from Reference 8 with a Kd of 6.2 µmol/L.

Voltage Dependence of Drug-Channel Interactions
Current-voltage relations for quasi–steady state current at the end of voltage steps, as in Fig 1Up, indicated that each drug reduced hKv1.5 current over a wide voltage range. To quantify the effects of voltage on the drug-channel interaction, we determined fractional block from the relative suppression of current at each voltage (see "Materials and Methods"). Fig 3Down shows typical examples and illustrates that the voltage dependence displayed a similar pattern for all three drugs. A steep phase was visible between -30 and -10 mV, which coincides with the steep voltage dependence of channel opening. An additional weaker voltage dependence was observed in the voltage range positive to 0 mV, over which the hKv1.5 channel is always open.3 The steepness of this shallow phase was e-fold per 120 to 150 mV. This voltage dependence can be explained if the positively charged nitrogen of TPeA and clofilium senses a fraction of the transmembrane electrical field at the binding site. When a single barrier model (Equation 3>, see "Materials and Methods") was used, the calculated fractional electrical distance was 0.19 and 0.15 for the examples shown in Fig 3Down, panels A and B, respectively. In the case of quinine (Fig 3CDown), a similar calculation yielded an equivalent electrical distance of 0.18, consistent with the predominantly cationic form of this drug at physiological pH (pKa=8.6 to 8.9). The TableDown summarizes the average values (n=4 to 6) for the electrical binding distance obtained in this manner. The values were close to 0.20, and no significant differences were observed between these drugs.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 3. Voltage dependence of hKv1.5 inhibition by tetrapentylammonium (TPeA, A), clofilium (B), and quinine (C). Typical examples are shown for concentrations that induced {approx}50% block. Current at the end of voltage steps in the presence of drug (Idrug) was normalized to matching control current (Icontrol) and converted to normalized block (1-Idrug/Icontrol) indicated by the open and closed circles. Because of the slow development of block, pulse duration was 750 milliseconds for TPeA and clofilium; for quinine, it was 250 milliseconds. Below -20 mV, the ratio was undefined (small or no current). The dashed line represents the voltage dependence of hKv1.5 activation. Vm indicates membrane voltage; {circ}, steep voltage dependence of block coinciding with channel activation; and {bullet}, shallow voltage dependence of block. Only the latter were used in the fit with the Woodhull model (Equation 3>; see "Materials and Methods"), shown by the solid line with the indicated values for the equivalent electrical distance ({delta}).


View this table:
[in this window]
[in a new window]
 
Table 1. Statistical Data for Clofilium, Tetrapentylammonium, Quinine, and Quinidine

Time Dependence of Drug-Channel Interactions
The results presented thus far dealt with steady state levels of inhibition. In the presence of clofilium or TPeA, a clear time-dependent decline of the current was observed after channel opening (Fig 1Up). If these drugs have a low affinity for the rested state of the channel but a high affinity for the open conformation, as suggested by the results in the previous sections, then this time dependence would represent the time course of relaxation toward a new equilibrium. The superimposed tracings at +60 mV (insets in Fig 4Down) illustrate that the rate of this relaxation was enhanced by increasing the drug concentration, consistent with the interpretation of this decay as the time course of open-channel block. This time-dependent block was observed over the entire voltage range at the higher concentrations for clofilium and TPeA (Fig 1CUp and 1FUp). In contrast, the tracings at -20 mV and -10 mV in 0.3 µmol/L clofilium (Fig 1EUp) did not display the same extensive time-dependent decline as the corresponding tracing at +50 mV. Thus, although the time dependence was obvious at voltages at which the channel activates quickly, it was apparently obscured by the slower activation at modest depolarizations. Therefore, we determined the rate of block from the inverse of the time constant of the drug-induced exponential component in the hKv1.5 time course at +50 and +60 mV.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 4. Rate of block induction as a function of drug concentration for clofilium (A) and tetrapentylammonium (TPeA, B). Insets, Superimposed raw hKv1.5 tracings at +60 mV. The numbers indicate the drug concentration in µmol/L. Calibration: (A) 250 milliseconds, amplitude normalized to control, (B) 125 milliseconds and 1 nA. The rate of block ({lambda}) was determined from exponential fits to the drug-induced decline of current during depolarization (n=3 to 6 at each concentration). The solid line represents the linear fit to the data (Equation 2>). The resulting apparent rate constants for association (k) and dissociation (l) are summarized in the TableUp.

For a bimolecular reaction, the rate of block is a linear function of the drug concentration (Equation 2). This was the case for both TPeA and clofilium, as shown in Fig 4Up, in which the solid line represents the linear least-squares fit to the data. From the latter, we obtained apparent rate constants for drug binding (k) and unbinding (l). Values and statistics are summarized in the TableUp, which for comparison also lists the values for quinidine obtained previously.8 Whereas the association rate constants differed less than twofold, the unbinding rate constants for clofilium and TPeA were an order of magnitude slower than that for quinidine.

Stereoselective Difference in Block by Quinidine and Quinine
Fig 5Down compares the effects of quinidine and quinine. The kinetic difference between both diastereomers is especially evident when comparing the tracings for 6 µmol/L quinidine and 20 µmol/L quinine, which induced comparable levels of block. With quinidine a time-dependent component of hKv1.5 block was evident (Fig 5ADown), as has been described in detail before.8 With quinine it was difficult to identify a time-dependent component of block after channel opening (although we occasionally observed a small and brief decaying transient). Nevertheless, the tracings in the presence of quinine were not a scaled-down version of the control current. Instead, the transition from the rising phase into the sustained current appeared more abrupt. As shown by the modeling (see "Discussion"), this is consistent with a fast interaction with the open state. To further illustrate the reversibility and the stereoselective difference between quinine and quinidine, Fig 5CDown shows the current-voltage relations for an experiment in which both drugs were applied in the same cell. Application of 20 µmol/L quinine induced 48% block at +50 mV. After a 20-minute washout, a virtually complete reversal of this effect was obtained. Subsequently, an equimolar concentration of quinidine was applied, inducing substantially more block (77%). Both levels of block were consistent with the apparent affinities from Fig 2Up.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 5. Comparison of the effects of quinidine and quinine. A, Time-dependent block by 2 and 6 µmol/L quinidine. With 6 µmol/L quinidine, a fast exponential component ({tau}B=19.7 milliseconds) was superimposed on the slow inactivation that was also present in the control condition. B, Suppression of hKv1.5 by 20 and 100 µmol/L quinine. No fast time-dependent component could be resolved, but the time to peak was shorter, especially at the higher concentration. Calibration for panels A and B was 100 milliseconds and 500 pA. C, Steady state current-voltage relations comparing quinine and quinidine in the same cell. The reduction of hKv1.5 current by 20 µmol/L quinine (48% at +50 mV) was completely reversed after washout. Subsequent exposure to an equimolar quinidine concentration resulted in more extensive suppression (77% at +50 mV).

Modification of Tail Current Time Course
If these drugs only interact with the open hKv1.5 channel, then blocked channels need to transit through the open state before they could deactivate to the rested state (see diagram in Fig 8Up). Thus, one would expect a modification of the deactivating tail currents. Fig 6Down shows tail currents in the control condition and after TPeA, clofilium, and quinine in concentrations that resulted in 30% to 60% block during the eliciting depolarization. Compared with the control condition, the tail currents in each case started at a lower amplitude, reflecting the depolarization-induced block. The subsequent decay was markedly slower than in the control condition, and superposition of tail currents in the control condition and in the presence of drug resulted in a "crossover" phenomenon (arrows in Fig 6Down).



View larger version (9K):
[in this window]
[in a new window]
 
Figure 6. Drug-induced slowing of deactivating tail current time course. A, Tetrapentylammonium (TPeA) at 1 µmol/L. B, Clofilium at 0.3 µmol/L. C, Quinine at 20 µmol/L. The tail current with the largest amplitude and fastest decline in each case represents control. For each drug, the initial tail current amplitude is reduced, reflecting the level of block, and the time course is slowed. Tail currents were recorded at -30 mV after steps to +50 mV for 500 milliseconds (A and B) or 250 milliseconds (C).

Effects Combined Application of TPeA and Quinine
To further determine whether quinine binds at the same (or an overlapping) site, we compared the effect of combined application of quinine and TPeA with TPeA alone. In these experiments, the cells were preincubated with TPeA for at least 30 minutes. If both drugs bind independently (ie, at different sites), then the addition of quinine would further reduce the current. Fig 7ADown shows that this was not the case. In the presence of both drugs, the peak current was suppressed, but the hKv1.5 current decayed much slower despite the higher total concentration of blockers. This resulted in a larger amount of current later during depolarization. Similar observations were made in five additional experiments. With sufficient separation in interaction rates, the relative blocking rate should be proportional to the relative suppression of current17 18 : (4) {lambda}TQ/{lambda}T=ITQ/IT



View larger version (13K):
[in this window]
[in a new window]
 
Figure 7. Competition between quinine and tetrapentylammonium (TPeA). A, Superposition of hKv1.5 currents at +50 mV in the presence and absence of 20 µmol/L quinine with 5 µmol/L TPeA present throughout. In the presence of quinine, both the peak current and the rate of block were suppressed to a similar degree relative to TPeA alone, with relative values of 0.63 and 0.58, respectively. B, Normalized rate of block ({lambda}TQ/{lambda}T) versus normalized peak current (ITQ/IT). Different symbols represent different experiments. The data show the progressive change along the line of proportionality (solid line) for data obtained at different time points during washout of quinine.

In this relation, {lambda}T and {lambda}TQ are the apparent blocking rates for TPeA and the TPeA/quinine combination, respectively; ITQ/IT is the fraction of remaining peak current in the TPeA/quinine combination versus TPeA. In four experiments with 20 µmol/L quinine, the relative peak amplitude averaged 0.68±0.03, and the relative blocking rate averaged 0.63±0.07 (n=4, P=NS). The above relation does not depend explicitly on the drug concentration and should be satisfied when the quinine concentration is changed in the continued presence of TPeA. This is illustrated for three experiments in Fig 7BUp. In each case, this proportionality was observed during administration or washout of quinine, as indicated by the clustering of the data around the predicted line.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
The main observations in the present study were as follows: (1) Block of hKv1.5 by tertiary amine drugs quinidine and quinine resembled that by quaternary ammonium drugs in state, time, and voltage dependence, pointing to a common mechanism (open-channel block). (2) Stereoselective differences exist between quinidine and quinine in affinity and kinetics of hKv1.5 block. (3) The high-affinity blockers displayed slow kinetics of block. (4) Quinine and TPeA displayed interaction, suggesting competition for a common site. (5) The difference in kinetics and affinity could be explained largely by the 100-fold range in the rate constants for drug dissociation from the channel receptor.

Block of the Open Conformation of hKv1.5
TPeA and clofilium both reduced the open-channel current (Figs 1Up and 4Up). Upon depolarization, the channel started to open as in the control condition and reached a peak current level that was only slightly depressed compared with the control condition (Fig 1BUp and 1EUp). This indicates that little or no channel block existed at -80 mV and that the kinetics of block were too slow to produce a significant level of inhibition before reaching the peak current level. The difference between absence of block at -80 mV and the high steady-state level of block upon depolarization is not consistent with a state-independent model for block. It indicates that channel opening is required before binding can occur. In this case, block is expected to track the voltage dependence of channel opening, explaining the steep phase of the voltage dependence of block in Fig 3Up.

Development of block by TPeA and clofilium was considerably slower than that produced by quinidine.8 The rate of block increased linearly with drug concentration (Fig 4Up), as expected for open-channel block. The derived association rate constant k for both drugs was similar to that for quinidine (TableUp). The main difference with quinidine was a 10-fold slower apparent unbinding rate for both drugs. These rate constants can also be used to estimate the apparent Kd (=l/k), yielding values of 0.8 and 0.25 µmol/L for TPeA and clofilium, respectively. This estimate is independent from the apparent Kd obtained from steady state current suppression (Fig 2Up, TableUp). Nevertheless, the values are in reasonable agreement, and the small differences probably result from the interference of the intrinsic slow inactivation of hKv1.5 with both measurements.

Fig 8AUp shows that mathematical simulations using an open-channel block model reproduced the essential features of the interaction between clofilium and hKv1.5, using the rate constants from the TableUp. With increasing drug concentration, both the extent of block and the rate of its development increased, similar to the experimental results (Figs 1Up and 4BUp). Fig 8AUp shows that the pure open-channel block model can also account for a concentration-dependent reduction in the peak outward current upon depolarization, as consistently seen in the experimental tracings (Figs 1Up and 4Up).

Fast Open-Channel Block Can Explain the Effects of Quinine
The lack of a clear time-dependent component of block after channel opening might suggest a different mechanism of action for quinine. However, observations supporting open-channel block include the biphasic voltage dependence of block similar to that for the quaternary compounds (Fig 3Up) and quinidine,8 the similar binding distance, and the tail current crossover (Fig 6CUp). Therefore, we tested whether a kinetic change in the open-channel block model was sufficient to account for the interaction of quinine with hKv1.5. Lacking a direct experimental measure of the binding rate, we reasoned as follows: If the more abrupt transition (compared with control) from the rising phase of channel opening into the reduced steady state level represents fast block, ie, block occurring on the time scale of channel opening, then the time constant for 20 µmol/L quinine should be <4 to 5 milliseconds. At the Kd, the forward rate kx[D] equals the off rate l, or the binding rate {lambda}(=kx[D]+l) equals 2l. With the constraint that the time constant should be <4 milliseconds, we would expect 2l to be >250 s-1 or l to be >125 s-1. Taking the latter lower limit of 125 s-1 for l, the association rate constant would be k=6 · s-1, ie, in the range of the binding rate constants for quinidine and the quaternary ammonium derivatives. Fig 8BUp shows the modeled-kinetics change in function of the dissociation rate constant for three hypothetical drugs that have the same association rate constant (k) and were applied in a concentration ([D]) corresponding to their Kd. The cases for l=2, 30, and 120 s-1 correspond roughly to clofilium, quinidine, and quinine, respectively. With an increase in the dissociation rate constant, the phasic component became faster and was reduced in amplitude. For l=120 s-1, the current was suppressed almost immediately, leaving only a small fast phasic component. In other simulations with l=200 s-1 and k=9.7 (µmol/L)-1 · s-1 (Kd=20.6 µmol/L), the phasic component was further reduced to <3% of the total amplitude (not shown). In actual experiments, it is not surprising that such small components cannot be resolved reliably and essentially appear as a sharp transition from the rising phase of the current into the blocked state. Thus, the lack of clearly resolved time dependence does not require the postulation of a separate mechanism for hKv1.5 block by quinine.

The data illustrated in Fig 7Up further address site and kinetics of quinine block. These results resemble the competitive interaction of internal TEA with N-type ("ball and chain") inactivation.17 18 With independent binding, the current in the presence of both drugs would be scaled down compared with TPeA alone. However, if the return from the TPeA blocked state is slow and if quinine interacts much faster, then the competitive scheme predicts that the apparent blocking rate is reduced proportionally to the depression of the peak current.17 18 This competition is further illustrated by the larger current (crossover) later in the step. This paradoxical increase in current is clearly inconsistent with independent binding but a logical consequence of the competition: channels blocked by either compound are nonconducting, but in the presence of quinine, the channels shuttle frequently between the short-lived blocked state and the open state. Each time the channel opens the probability to become blocked again by quinine exceeds that of becoming "irreversibly" blocked by TPeA. Thus, these data further demonstrate that quinine interacts with hKv1.5 significantly faster than does TPeA but binds at the same or a nearby site.

Electrostatic Effect of the Transmembrane Electrical Field on Drug Binding
As shown in Fig 3Up, a shallow voltage dependence of binding was observed positive to 0 mV, which is the voltage range over which the hKv1.5 channel is fully open.3 In terms of drug-channel interaction, this effect could result from properties of the drug or the receptor. It is conceivable that the affinity of the open-channel receptor displays itself an intrinsic and continuous voltage dependence. As argued elsewhere,8 this is unlikely, and a simpler explanation is that these charged drugs bind at a receptor site within the transmembrane electrical field. The electrical distance calculated from the Woodhull model (Snyders et al8 ) was 0.19 for quinidine, and comparable values were obtained for the drugs in the present study (Fig 3Up, TableUp). This indicates binding at a site {approx}20% into the transmembrane electrical field as referenced from the intracellular side. The similarity in this binding distance and the similarity in the overall mechanism of hKv1.5 inhibition strongly suggest that all these drugs bind either at the same receptor or at least that when bound to their receptors, the positively charged amine is approximately in the same position.

In Shaker channels, residues at the putative innermost turn of the P loop and in the carboxyl terminal half of S6 have been implicated in the binding of quaternary ammonium derivatives, including clofilium.10 19 The electrical binding distance obtained for the drugs in the present study is similar to the value observed for internal TEA block of Shaker channels.10 20 The affinity observed for TPeA in this human Shaker-like channel is very similar to the affinity of the longer chain N-alkyltriethylammonium derivatives in the Shaker channel.10 Both affinity and interaction rate constants for TPeA are also very similar to those obtained for Kv1.6.21 Our results with clofilium are in agreement with those obtained by Malayev et al22 in terms of affinity, kinetics during depolarization, and overall interpretation as open-channel block from the inside. The slow dissociation rate (TableUp) may correspond to the fast component of recovery from block in their study.

The shallow voltage dependence observed positive to 0 mV for each of the drugs in the present study is similar to that obtained for other blockers of hKv1.5, such as terfenadine,23 24 verapamil,25 and bupivacaine.26 Thus, the electrical field appears to influence drug binding in a similar fashion for each of these drugs, consistent with a common binding site for antiarrhythmic drugs in the internal mouth of the channel. Nevertheless, this electrostatic component may not contribute much to the binding energy, because it is similar for these drugs despite a 100-fold difference in affinity. The main effect of this electrostatic component may be either to facilitate diffusion to the binding site or to help orient the molecule in a favorable way for binding at the receptor.

Hydrophobic Determinant of Block
The second determinant of binding is suggested by the large range of apparent dissociation rate constants. These did correlate well with the changes in affinity, which suggests that they reflect a large fraction of the binding energy (TableUp). The dissociation rate constant reflects the stability of the drug-receptor complex. Because the electrostatic component is similar, as is the charge on these drugs, we propose that this indicates that hydrophobic interactions are important in determining the stability of the drug-channel complex. A similar explanation was proposed for the interaction of various quaternary TEA derivatives with squid potassium channels9 27 and for the interaction of TEA analogues with Shaker channels.10 Such a model could also explain the seemingly paradoxical result that the affinity for open sodium channel blockers correlated strongly with their hydrophobicity, as judged from their logP.28 Thus, these open-channel blockers appear to gain access to the receptor via a hydrophilic pathway,29 but hydrophobic interactions with the wall of the internal mouth of the channel appear to be the major determinant of the affinity. Interestingly, the polar substitution on the aromatic ring of the methanesulfonanilide class III drugs seems to be incompatible with the structure of the binding site in these channels, because no block was detected with 1 mmol/L D-sotalol30 or 1 µmol/L dofetilide (authors' unpublished observations, 1994).

Our results with the quaternary drugs display similarity with clofilium block of batrachotoxin-modified sodium channels for which hydrophobic interactions were proposed,31 and with block of normal cardiac sodium channels by quarternary drugs.32 33 34 Furthermore, the S6 segment of domain IV of a cloned sodium channel has been implicated in the binding of local anesthetics.35 The similarity may reflect a common tertiary structure of the internal vestibule of these voltage-gated ion channels.

Conclusion
In summary, we propose that binding of several class III antiarrhythmic drugs to hKv1.5 potassium channels is determined by an electrostatic component reflected in the electrical binding distance and a hydrophobic component that determines the affinity and depends on the nature and orientation (stereoselectivity) of the side chains. Because of the similarity between the S6 segment of these potassium channels with the corresponding segment in domain IV of sodium and calcium channels, this may represent a general set of determinants for drug binding in the internal mouth of voltage-gated ion channels. An unresolved question is why these channels have such a binding site, but one could speculate that these drugs use a structure that is needed for normal channel function.


*    Acknowledgments
 
This study was supported by National Institutes of Health grants HL-47599 and HL-46681. The authors wish to thank Drs Roden and Tamkun and Mr Rich for review of the manuscript, Dr Bennett for helpful discussions, Mr Short and Mr Kodali for technical help, and Mr Sheffer for secretarial help.


*    Footnotes
 
Reprint requests to Dirk J. Snyders, MD, 554-MRB2, Vanderbilt University School of Medicine, Nashville, TN 37232-6602.

Previously presented as preliminary results in abstract form (Biophys J. 1992;61:151a and Circulation. 1992;86[suppl I]:I-26).

Received July 8, 1994; accepted May 31, 1995.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Gintant GA, Cohen IS, Datyner NB, Kline RP. Time-dependent outward currents in the heart. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System: Scientific Foundations. New York, NY: Raven Press Publishers; 1992:1121-1169.

2. Vaughan-Williams EM. Classification of antiarrhythmic actions. In: Vaughan-Williams EM, ed. Handbook of Experimental Pharmacology. 1989;89:45-62.

3. Snyders DJ, Tamkun MM, Bennett PB. A rapidly activating and slowly inactivating potassium channel cloned from human heart: functional analysis after stable mammalian cell culture expression. J Gen Physiol. 1993;101:513-543. [Abstract/Free Full Text]

4. Boyle WA, Nerbonne JM. A novel type of depolarization-activated K+ current in adult rat atrial myocytes. Am J Physiol. 1991;260:H1236-H1247. [Abstract/Free Full Text]

5. Boyle WA, Nerbonne JM. Two functionally distinct 4-aminopyridine sensitive outward K+ currents in rat atrial myocytes. J Gen Physiol. 1992;100:1041-1067. [Abstract/Free Full Text]

6. Jeck CD, Boyden PA. Age-related appearance of outward currents may contribute to developmental differences in ventricular repolarization. Circ Res. 1992;71:1390-1403. [Abstract/Free Full Text]

7. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73:1061-1076. [Abstract/Free Full Text]

8. Snyders DJ, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992;41:322-330. [Abstract]

9. Armstrong CM. Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol. 1971;58:413-437. [Abstract/Free Full Text]

10. Choi KL, Mossman C, Aube J, Yellen G. The internal quaternary ammonium receptor site of Shaker potassium channels. Neuron. 1993;10:533-541. [Medline] [Order article via Infotrieve]

11. Arena JP, Kass RS. Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked. Mol Pharmacol. 1988;34:60-66. [Abstract]

12. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100. [Medline] [Order article via Infotrieve]

13. Woodhull AM. Ionic blockade of sodium channels in nerve. J Gen Physiol. 1973;61:687-708. [Abstract/Free Full Text]

14. Bezanilla F, Perozo E, Stefani E. Gating of Shaker K+ channels, II: the components of gating currents and a model of channel activation. Biophys J. 1994;66:1011-1021. [Medline] [Order article via Infotrieve]

15. Zagotta WN, Hoshi T, Aldrich RW. Shaker potassium channel gating, III: evaluation of kinetic models for activation. J Gen Physiol. 1994;103:321-362. [Abstract/Free Full Text]

16. Hansch G, Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. New York, NY: John Wiley & Sons Inc; 1979.

17. Choi KL, Aldrich RW, Yellen G. Tetraethylammonium blockade distinguishes two inactivation mechanisms in voltage-activated K+ channels. Proc Natl Acad Sci U S A. 1991;88:5092-5095. [Abstract/Free Full Text]

18. Grissmer S, Cahalan M. TEA prevents inactivation while blocking open K+ channels in human T lymphocytes. Biophys J. 1989;55:203-206.[Medline] [Order article via Infotrieve]

19. Yool AJ. Block of the inactivating potassium channel by clofilium and hydroxylamine depends on the sequence of the pore region. Mol Pharmacol. 1994;46:970-976. [Abstract]

20. Yellen G, Jurman ME, Abramson T, MacKinnon R. Mutations affecting internal TEA blockade identify the probable pore-forming region of a K+ channel. Science. 1991;251:939-942. [Abstract/Free Full Text]

21. Kirsch GE, Taglialatela M, Brown AM. Internal and external TEA block in single cloned K+ channels. Am J Physiol. 1991;261:C583-C590. [Abstract/Free Full Text]

22. Malayev AA, Nelson DJ, Philipson LH. Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995;47:198-205.[Abstract]

23. Rampe D, Wible B, Brown AM, Dage RC. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol. 1993;44:1240-1245. [Abstract]

24. Yang T, Prakash C, Roden DM, Snyders DJ. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and its enantiomers. Br J Pharmacol. 1995;115:267-274. [Medline] [Order article via Infotrieve]

25. Rampe D, Wible B, Fedida D, Dage RC, Brown AM. Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart. Mol Pharmacol. 1993;44:642-648. [Abstract]

26. Valenzuela C, Delpon E, Tamkun MM, Tamargo J, Snyders DJ. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J. 1995;69:418-427. [Medline] [Order article via Infotrieve]

27. Swenson RP. Inactivation of potassium current in squid axon by a variety of quaternary ammonium ions. J Gen Physiol. 1981;77:255-271. [Abstract/Free Full Text]

28. Ehring GR, Moyer JW, Hondeghem LM. Quantitative structure activity studies of antiarrhythmic properties in a series of lidocaine and procainamide derivatives. J Pharmacol Exp Ther. 1988;244:479-492. [Abstract/Free Full Text]

29. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977;69:497-515. [Abstract/Free Full Text]

30. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994;45:1227-1234. [Abstract]

31. Wang GK, Simon R, Bell D, Mok WM, Wang S. Structural determinants of quaternary ammonium blockers for batrachotoxin-modified Na+ channels. Mol Pharmacol. 1994;44:667-676. [Abstract]

32. Gingrich KJ, Beardsley D, Yue DT. Ultra-deep blockade of Na+ channels by a quaternary ammonium ion: catalysis by a transition-intermediate state? J Physiol (Lond). 1993;471:319-341. [Abstract/Free Full Text]

33. Nettleton J, Castle NA, Wang GK. Block of single batrachotoxin-activated Na+ channels by clofilium. Mol Pharmacol. 1991;39:352-358. [Abstract]

34. O'Leary ME, Horn R. Internal block of human heart sodium channels by symmetrical tetra-alkylammoniums. J Gen Physiol. 1994;104:507-522. [Abstract/Free Full Text]

35. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science. 1994;265:1724-1728.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Circ. Res.Home page
S. M. Schumacher, D. P. McEwen, L. Zhang, K. L. Arendt, K. M. Van Genderen, and J. R. Martens
Antiarrhythmic Drug-Induced Internalization of the Atrial-Specific K+ Channel Kv1.5
Circ. Res., June 19, 2009; 104(12): 1390 - 1398.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Decher, P. Kumar, T. Gonzalez, B. Pirard, and M. C. Sanguinetti
Binding Site of a Novel Kv1.5 Blocker: A "Foot in the Door" against Atrial Fibrillation
Mol. Pharmacol., October 1, 2006; 70(4): 1204 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Decher, P. Kumar, T. Gonzalez, V. Renigunta, and M. C. Sanguinetti
Structural Basis for Competition between Drug Binding and Kv{beta}1.3 Accessory Subunit-Induced N-Type Inactivation of Kv1.5 Channels
Mol. Pharmacol., October 1, 2005; 68(4): 995 - 1005.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. H. Choi, J.-A. Park, K.-R. Kim, G.-I. Lee, Y.-T. Lee, H. Choe, S.-H. Ko, M.-H. Kim, Y.-H. Seo, and Y.-G. Kwak
Direct block of cloned hKv1.5 channel by cytochalasins, actin-disrupting agents
Am J Physiol Cell Physiol, August 1, 2005; 289(2): C425 - C436.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
R. E. Garcia-Ferreiro, D. Kerschensteiner, F. Major, F. Monje, W. Stuhmer, and L. A. Pardo
Mechanism of Block of hEag1 K+ Channels by Imipramine and Astemizole
J. Gen. Physiol., September 27, 2004; 124(4): 301 - 317.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. C. Vargas, S. Tenreiro, M. C. Teixeira, A. R. Fernandes, and I. Sa-Correia
Saccharomyces cerevisiae Multidrug Transporter Qdr2p (Yil121wp): Localization and Function as a Quinidine Resistance Determinant
Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2531 - 2537.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Decher, B. Pirard, F. Bundis, S. Peukert, K.-H. Baringhaus, A. E. Busch, K. Steinmeyer, and M. C. Sanguinetti
Molecular Basis for Kv1.5 Channel Block: CONSERVATION OF DRUG BINDING SITES AMONG VOLTAGE-GATED K+ CHANNELS
J. Biol. Chem., January 2, 2004; 279(1): 394 - 400.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
S. Wang, M. J Morales, Y.-J. Qu, G. C L Bett, H. C Strauss, and R. L Rasmusson
Kv1.4 channel block by quinidine: evidence for a drug-induced allosteric effect
J. Physiol., January 15, 2003; 546(2): 387 - 401.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Caballero, I. Moreno, T. Gonzalez, C. Valenzuela, J. Tamargo, and E. Delpon
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)
Cardiovasc Res, October 1, 2002; 56(1): 104 - 117.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Godreau, R. Vranckx, and S. N. Hatem
Mechanisms of Action of Antiarrhythmic Agent Bertosamil on hKv1.5 Channels and Outward Potassium Current in Human Atrial Myocytes
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 612 - 620.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Perchenet, L. Hilfiger, J. Mizrahi, and O. Clement-Chomienne
Effects of Anorexinogen Agents on Cloned Voltage-Gated K+ Channel hKv1.5
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1108 - 1119.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Iftinca, G. J. Waldron, C. R. Triggle, and W. C. Cole
State-Dependent Block of Rabbit Vascular Smooth Muscle Delayed Rectifier and Kv1.5 Channels by Inhibitors of Cytochrome P450-Dependent Enzymes
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 718 - 728.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
M. W. Brock, C. Mathes, and W. F. Gilly
Selective Open-Channel Block of Shaker (Kv1) Potassium Channels by S-Nitrosodithiothreitol (Sndtt)
J. Gen. Physiol., July 1, 2001; 118(1): 113 - 134.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Wang, A. Y. Xiao, T. Ichinose, and S. P. Yu
Effects of Tetraethylammonium Analogs on Apoptosis and Membrane Currents in Cultured Cortical Neurons
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 524 - 530.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
B. H. Choi, J.-S. Choi, S.-W. Jeong, S. J. Hahn, S. H. Yoon, Y.-H. Jo, and M.-S. Kim
Direct Block by Bisindolylmaleimide of Rat Kv1.5 Expressed in Chinese Hamster Ovary Cells
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 634 - 640.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
L. Yue, J. L. Feng, Z. Wang, and S. Nattel
Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes
Cardiovasc Res, April 1, 2000; 46(1): 151 - 161.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. Delpon, R. Caballero, C. Valenzuela, M. Longobardo, D. Snyders, and J. Tamargo
Benzocaine enhances and inhibits the K+ current through a human cardiac cloned channel (Kv1.5)
Cardiovasc Res, May 1, 1999; 42(2): 510 - 520.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. L. Cogolludo, F. Perez-Vizcaino, and J. Tamargo
Antagonism by Class I Antiarrhythmic Drugs of Levcromakalim-Induced Relaxation in Isolated Rat Aorta
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 81 - 86.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
Y. Lu, L. Yue, Z. Wang, and S. Nattel
Effects of the Diuretic Agent Indapamide on Na+, Transient Outward, and Delayed Rectifier Currents in Canine Atrial Myocytes
Circ. Res., July 27, 1998; 83(2): 158 - 166.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Longobardo, E. Delpón, R. Caballero, J. Tamargo, and C. Valenzuela
Structural Determinants of Potency and Stereoselective Block of hKv1.5 Channels Induced by Local Anesthetics
Mol. Pharmacol., July 1, 1998; 54(1): 162 - 169.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Cell Physiol.Home page
V. N. Uebele, S. K. England, D. J. Gallagher, D. J. Snyders, P. B. Bennett, and M. M. Tamkun
Distinct domains of the voltage-gated K+ channel Kvbeta 1.3 beta -subunit affect voltage-dependent gating
Am J Physiol Cell Physiol, June 1, 1998; 274(6): C1485 - C1495.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
F. S.P. Chen and D. Fedida
On the Mechanism by which 4-Aminopyridine Occludes Quinidine Block of the Cardiac K+ Channel, hKv1.5
J. Gen. Physiol., April 1, 1998; 111(4): 539 - 554.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Franqueza, M. Longobardo, J. Vicente, E. Delpon, M. M. Tamkun, J. Tamargo, D. J. Snyders, and C. Valenzuela
Molecular Determinants of Stereoselective Bupivacaine Block of hKv1.5 Channels
Circ. Res., December 19, 1997; 81(6): 1053 - 1064.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Zhang, J. W. Anderson, and D. Fedida

J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1247 - 1256.
[Abstract] [Full Text]


Home page
CirculationHome page
C. Valenzuela, E. Delpon, L. Franqueza, P. Gay, O. Perez, J. Tamargo, and D. J. Snyders
Class III Antiarrhythmic Effects of Zatebradine: Time-, State-, Use-, and Voltage-Dependent Block of hKv1.5 Channels
Circulation, August 1, 1996; 94(3): 562 - 570.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
S. W. Yeola, T. C. Rich, V. N. Uebele, M. M. Tamkun, and D. J. Snyders
Molecular Analysis of a Binding Site for Quinidine in a Human Cardiac Delayed Rectifier K+ Channel : Role of S6 in Antiarrhythmic Drug Binding
Circ. Res., June 1, 1996; 78(6): 1105 - 1114.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
V. N. Uebele, S. K. England, A. Chaudhary, M. M. Tamkun, and D. J. Snyders
Functional Differences in Kv1.5 Currents Expressed in Mammalian Cell Lines Are Due to the Presence of Endogenous Kvbeta2.1 Subunits
J. Biol. Chem., February 2, 1996; 271(5): 2406 - 2412.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. H. Choi, J.-S. Choi, D.-J. Rhie, S. H. Yoon, D. S. Min, Y.-H. Jo, M.-S. Kim, and S. J. Hahn
Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor
Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1461 - C1468.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snyders, D. J.
Right arrow Articles by Yeola, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyders, D. J.
Right arrow Articles by Yeola, S. W.